title: Chloroquine or sulfadoxine-pyrimethamine for the treatment of uncomplicated, Plasmodium falciparum malaria during an epidemic in Central Java, Indonesia.
abstract: A recent malaria epidemic in the Menoreh Hills of Central Java has increased concern about the re-emergence of endemic malaria on Java, which threatens the island's 120 million residents. A 28-day, in-vivo test of the efficacy of treatment of malaria with antimalarial drugs was conducted among 167 villagers in the Menoreh Hills. The treatments investigated, chloroquine (CQ) and sulfadoxine-pyrimethamine (SP), constitute, respectively, the first- and second-line treatments for uncomplicated malaria in Indonesia. The prevalence of malaria among 1389 residents screened prior to enrollment was 33%. Treatment outcomes were assessed by microscopical diagnoses, PCR-based confirmation of the diagnoses, measurement of the whole-blood concentrations of CQ and desethylchloroquine (DCQ), and identification of the Plasmodium falciparum genotypes. The 28-day cumulative incidences of therapeutic failure for CQ and SP were, respectively, 47% (N = 36) and 22% (N = 50) in the treatment of P. falciparum, and 18% (N = 77) and 67% (N = 6) in the treatment of P. vivax. Chloroquine was thus an ineffective therapy for P. falciparum malaria, and the presence of CQ-resistant P. vivax and SP-resistant P. falciparum will further compromise efforts to control resurgent malaria on Java.
authors.affiliation: U.S. Naval Medical Research Unit #2, U.S. Embassy Jakarta, Unit 8132, NAMRU-TWO, FPO AP 96520-8132, USA. maguirejd@namru2.navy.mil
authors.forename: J D
authors.initials: JD
authors.lastname: Maguire
authors.forename: M D
authors.initials: MD
authors.lastname: Lacy
authors.lastname: Sururi
authors.forename: P
authors.initials: P
authors.lastname: Sismadi
authors.lastname: Krisin
authors.forename: I
authors.initials: I
authors.lastname: Wiady
authors.forename: B
authors.initials: B
authors.lastname: Laksana
authors.forename: M J
authors.initials: MJ
authors.lastname: Bangs
authors.forename: S
authors.initials: S
authors.lastname: Masbar
authors.forename: I
authors.initials: I
authors.lastname: Susanti
authors.forename: W
authors.initials: W
authors.lastname: Basuki
authors.forename: M J
authors.initials: MJ
authors.lastname: Barcus
authors.forename: H
authors.initials: H
authors.lastname: Marwoto
authors.forename: M D
authors.initials: MD
authors.lastname: Edstein
authors.forename: S
authors.initials: S
authors.lastname: Tjokrosonto
authors.forename: J K
authors.initials: JK
authors.lastname: Baird
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002738:Chloroquine / Q000627:therapeutic use*; D004196:Disease Outbreaks; D004338:Drug Combinations; D004351:Drug Resistance; D005260:Female; D006801:Humans; D015994:Incidence; D007214:Indonesia / Q000453:epidemiology; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000453:epidemiology / Q000469:parasitology; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011739:Pyrimethamine / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000627:therapeutic use*; D017211:Treatment Failure
chemical_list: D000962:Antimalarials; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D002738:Chloroquine; D011739:Pyrimethamine